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AKI is a serious condition that affects at least 1 out of 2 critically ill patients and is associated with adverse short- and long-term outcomes.[@bib1], [@bib2] About 50% of patients with AKI requiring renal replacement therapy in the ICU die in the hospital, and AKI survivors have an excess risk of mortality over the following years.[@bib3], [@bib4], [@bib5], [@bib6] Other dire sequelae of AKI include the development and progression of CKD or end-stage renal disease.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15] Conversely, CKD patients carry an elevated risk of AKI, so that AKI and CKD predispose to each other in a vicious circle and may exert negative impacts independently or synergistically.[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22] Approximately 30% of critically ill AKI patients have underlying CKD.[@bib23], [@bib24] CKD by itself portends worse outcomes in hospitalized patients and is associated with a marked increase in the long-term risk of death and cardiovascular events.[@bib25], [@bib26], [@bib27]

Both AKI and CKD confer adverse prognosis; however, whether and how their coexistence affects outcomes has not been well elucidated. In several observational studies, AKI on CKD patients were found unexpectedly to have better in-hospital outcomes than their counterparts with AKI but without CKD, including shorter length of hospital stay and lower mortality rates.[@bib28], [@bib29], [@bib30], [@bib31], [@bib32] As for long-term outcomes in AKI survivors, pre-existing CKD has been associated with higher risk of progression to end-stage renal disease and death.[@bib32], [@bib33], [@bib34], [@bib35], [@bib36] Nevertheless, the great majority of these studies adopted heterogeneous, nonconsensus definitions of AKI, and did not take into account the severity of AKI episodes, thus making it difficult to fully appreciate the prognostic impact of AKI on CKD for clinical practice and research purposes.

The objective of our study was to examine how the combination of prevalent CKD and incident AKI, defined by the KDIGO criteria and stratified by AKI severity,[@bib37] are related to short- and long-term outcomes in critically ill septic patients, a setting in which both CKD and AKI are common and overall prognosis is dismal.[@bib38], [@bib39], [@bib40], [@bib41]

Methods {#sec1}
=======

Population and Variables {#sec1.1}
------------------------

We conducted a single-center, retrospective cohort study of patients admitted to the ICU in an urban tertiary care hospital. The observation period was from May 2007 to April 2012. Clinical variables were extracted from electronic health records (EHRs) and validated through comprehensive individual review of 10% of EHRs by data management personnel blinded to the study.

The analysis included adult (≥18 years old) patients who were admitted to the ICU with a diagnosis of severe sepsis or septic shock, defined on the basis of International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) codes, as per the criteria of Angus *et al.*,[@bib42] and had at least 1 serum creatinine (sCr) measurement during the 3 months prior to the index hospitalization. The closest sCr \>1 day and \<3 months before the index hospitalization was used to calculate the baseline estimated glomerular filtration rate (eGFR) through the 4-variable Modification of Diet in Renal Disease (MDRD) study equation.[@bib43] A cutoff of 60 ml/min per 1.73 m^2^ eGFR was used to define CKD at baseline (eGFR ≥60 ml/min per 1.73 m^2^ = no-CKD; eGFR \<60 ml/min per 1.73 m^2^ = CKD). Patients with end-stage renal disease or baseline eGFR \<15 ml/min per 1.73 m^2^ were excluded. AKI was defined as ≥26.4 μmol/l (0.3 mg/dl) or 50% increase in sCr from baseline to the peak value during the ICU stay and was graded according to KDIGO SCr criteria.[@bib37] Patients were then classified as no-AKI, AKI 1 (AKI stage 1), or AKI ≥2 (AKI stage 2 or 3).

Comorbidities were identified through ICD-9-CM codes, except anemia, which was defined as admission hematocrit \<39% for men and \<36% for women. Data regarding drug exposure (within 72 hours of ICU stay), red blood cell transfusion (within 72 hours of ICU stay), and mechanical ventilation during ICU stay were derived from hospital billing codes. Scores of critical illness severity (Sequential Organ Failure Assessment \[SOFA\][@bib44] and Acute Physiology and Chronic Health Evaluation II \[APACHE II\][@bib45]) scores were calculated on the basis of clinical and laboratory data within the first 24 hours of ICU admission. The SOFA score was expressed as "nonrenal SOFA," equivalent to the SOFA score minus the points attributed for renal function.

Study Outcomes {#sec1.2}
--------------

Two outcomes were evaluated: (i) 90-day mortality, defined as all-cause mortality during the index hospitalization or up to 90 days following hospital discharge, as captured from EHRs; and (ii) incident/progressive CKD, determined by comparing baseline eGFR (before index hospitalization) with the follow-up eGFR derived from the mean of the last 2 sCr measurements (91% of subjects) or last sCr measurement (9% of subjects) available in the EHRs, and obtained at least 90 days after hospital discharge. The definitions of incident and progressive CKD were adapted from the ones proposed in the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study.[@bib46] Specifically, incident CKD was defined in no-CKD patients who had a reduction in eGFR of at least 25% relative to baseline and reached an eGFR \<60 ml/min per 1.73 m^2^. Progressive CKD was defined in patients with pre-existent CKD as a decrease in eGFR of at least 50% relative to baseline or progression to CKD Stage 5 (eGFR \<15 ml/min per 1.73 m^2^). The documentation of renal replacement therapy sessions reported in the EHRs during the follow-up period was adopted as an alternative criterion to adjudicate incident or progressive CKD. Death events were also captured from the EHRs.

Statistical Analyses {#sec1.3}
--------------------

Study subjects were classified into 6 groups according to baseline eGFR (no-CKD, CKD) and AKI status during the ICU stay (no-AKI; AKI Stage 1; AKI Stages ≥2). Categorical data were reported as percentages, and continuous variables as mean ± SD or median (25th−75th percentile) according to data distribution. Comparisons between groups for categorical variables were made using the Fisher exact test. Continuous variables were compared with analysis of variance and model pairwise contrasts or with Kruskal−Wallis tests as per data distribution. Trends of variables across AKI categories were tested by Jonckheere−Terpstra and Cochran−Armitage trend tests for continuous and categorical variables, respectively. Two-sided *P* values \<0.05 were considered statistically significant.

The CKD/AKI groups were modeled as categorical predictors for study outcomes in Cox regression hazard models. The interaction between CKD and AKI was assessed for both study outcomes and, since a significant interaction (AKI×CKD) was identified for 1 of the study outcomes (incident/progressive CKD, *P* = 0.079), we present all models using the no-CKD/no-AKI group as the reference group for comparison to the other 5 groups. The interaction between SOFA score and CKD/AKI groups was nonsignificant for both study outcomes. The proportional hazards assumption was satisfied for all study outcomes and tested by interaction of time and predictor and graphic assessment.

Candidate variables tested as confounders included demographic data, comorbidity-related factors, and indicators of critical illness severity. Two multivariable models were generated. Model 1 included the following variables: age, gender, race; the presence of diabetes, systolic heart failure and anemia; nonrenal SOFA score, the need for mechanical ventilation; the exposure to red blood cell transfusion or statins, and the length of hospital stay (the latter only for the outcome of incident/progressive CKD). Model 2 included variables deemed of particular clinical relevance (age, gender, race, diabetes), together with additional variables that were retained through backward selection (cut-off for retention: *P* \< 0.10). In the event of collinearity between variables (SOFA and APACHE II scores), only 1 of 2 variables was included. Data analysis and figures were generated using SAS 9.4 (SAS Institute, Cary, NC) and GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).

Sensitivity Analyses {#sec1.4}
--------------------

### Examination of AKI Stage 1 Based on Absolute and Relative Changes in sCr {#sec1.4.1}

We reclassified cases of AKI stage 1 into 2 groups: (i) AKI 1-absolute: patients who had an absolute increase in sCr ≥26.4 μmol/l (0.3 mg/dl) from baseline and only a relative increase in sCr \<1.5 times baseline; and (ii) AKI 1-relative: patients with a relative increase in sCr 1.5 to 1.9 times baseline, independently of absolute sCr changes. When combined with CKD status and the other AKI groups, this reclassification of AKI stage 1 cases resulted in 8 CKD/AKI groups. These groups were used as categorical predictors for study outcomes in Cox regression hazard models, similarly to our primary analysis.

### Examination of Potential Misclassification of AKI as CKD When Assessing CKD Outcome {#sec1.4.2}

We evaluated the reclassification of the CKD outcome when single last sCr versus the mean of the last 2 sCr measurements was used in patients with follow-up sCr measurements \<7 days apart. We excluded the reclassified patients from the analysis in addition to patients with the upper and lower 2.5% of the distribution for percentage change in follow-up eGFR from baseline to avoid implausible extrapolation of associations at the extremes of the distribution where statistical power was lower.

Results {#sec2}
=======

Clinical Characteristics {#sec2.1}
------------------------

[Figure 1](#fig1){ref-type="fig"} details how the cohort was generated. Of the 2632 patients included in the current analysis, 46% had baseline CKD and 57% developed AKI during the ICU stay. Within the CKD group, 77.8% of cases had a baseline eGFR between 30 and 60 ml/min per 1.73 m^2^. The overall incidence of AKI was similar in patients with and without baseline CKD (56% vs. 58%, respectively, *P* = 0.252).Figure 1Study cohort derivation. AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; ICU, intensive care unit; sCr, serum creatinine.

Clinical characteristics of patients, stratified by the 6 CKD/AKI groups, are summarized in [Table 1](#tbl1){ref-type="table"}. The severity of AKI ≥2 was distributed as follows: 264 patients (34.3%) had AKI stage 2, 268 (34.8%) had stage 3, and 238 (30.9%) had stage 3 requiring renal replacement therapy. Relative to no-CKD, CKD subjects were older and more frequently had diabetes. Exposure to i.v. or intra-arterial iodinated contrast and aminoglycosides was significantly lower in CKD patients. In contrast, CKD patients were more likely to be prescribed diuretics and statins. The need for vasoactive drugs (pressors or inotropes) and for mechanical ventilation support and indexes of severity of illness increased in parallel with presence and severity of AKI, both in no-CKD and in CKD patients. There were no major differences in critical illness severity indicators between groups with the same AKI status, either with or without baseline CKD ([Table 1](#tbl1){ref-type="table"}).Table 1Demographic and clinical characteristics of the study cohort by the 6 CKD/AKI groupsCharacteristicsno-CKD/no-AKI n = 598no-CKD/AKI 1 n = 363no-CKD/AKI≥2 n = 460CKD/no-AKI n = 537CKD/AKI 1 n = 364CKD/AKI ≥2 n = 310**Demographics**Age, yr61.8 ± 16.564.4 ± 16.0[a](#tbl1fna){ref-type="table-fn"}61.2 ± 15.370.5 ± 14.6[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}70.8 ± 14.3[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}66.9 ± 14.1[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}^,^[d](#tbl1fnd){ref-type="table-fn"}Men, %55.960.156.545.1[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}46.4[a](#tbl1fna){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}58.1[e](#tbl1fne){ref-type="table-fn"}African American, %41.543.850.3[a](#tbl1fna){ref-type="table-fn"}^,^[d](#tbl1fnd){ref-type="table-fn"}33.1[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}34.9[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}43.2[d](#tbl1fnd){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}**Comorbidities**Baseline sCr, μmol/l80 (71--97)88 (71--97)[a](#tbl1fna){ref-type="table-fn"}80 (62--97)141 (115--186)[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}133 (115--168)[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}150 (124--221)[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}Baseline eGFR, ml/min per 1.73 m^2^84.5 (70.8--105.1)80.7 (69.1--94.9)[a](#tbl1fna){ref-type="table-fn"}88.1 (70.8--110.5)41.5 (30.3--50.6)[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}44.7 (37.4--51.3)[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}39.6 (28.1--50.7)[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}Diabetes, %17.123.1[a](#tbl1fna){ref-type="table-fn"}18.025.7[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}26.4[b](#tbl1fnb){ref-type="table-fn"}25.2[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}Systolic heart failure, %3.04.71.72.64.15.2[f](#tbl1fnf){ref-type="table-fn"}Anemia, %85.582.489.7[a](#tbl1fna){ref-type="table-fn"}86.490.0[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}88.3**Drug exposure**Diuretics[g](#tbl1fng){ref-type="table-fn"}, %39.553.2[b](#tbl1fnb){ref-type="table-fn"}40.448.6[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}55.8[b](#tbl1fnb){ref-type="table-fn"}47.4[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}Statins[g](#tbl1fng){ref-type="table-fn"}, %26.830.619.8[a](#tbl1fna){ref-type="table-fn"}^,^[d](#tbl1fnd){ref-type="table-fn"}35.9[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}42.9[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}30.0[f](#tbl1fnf){ref-type="table-fn"}Iodine contrast[g](#tbl1fng){ref-type="table-fn"}, %34.333.620.4[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}21.2[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}15.9[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}14.8[b](#tbl1fnb){ref-type="table-fn"}^,^[d](#tbl1fnd){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}Aminoglycosides[g](#tbl1fng){ref-type="table-fn"}, %11.512.411.56.5[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}6.3[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}6.1[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}**Critical illness indicators**Oliguria, %3.35.721.8[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}5.49.3[b](#tbl1fnb){ref-type="table-fn"}32.2[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}CFB at 72 h, L2.8 ± 5.43.5 ± 6.67.3 ± 7.7[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}2.8 ± 5.62.6 ± 6.06.1 ± 8.5[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}LOS, d12 (7--22)11 (6--18)[a](#tbl1fna){ref-type="table-fn"}13 (7--24)12 (7--20)[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}11 (6--18)[b](#tbl1fnb){ref-type="table-fn"}15 (7--26)[d](#tbl1fnd){ref-type="table-fn"}Pressors or inotropes[g](#tbl1fng){ref-type="table-fn"}, %28.834.451.3[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}27.735.4[a](#tbl1fna){ref-type="table-fn"}50.3[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}Mechanical ventilation, %38.143.052.6[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}35.640.148.4[a](#tbl1fna){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}RBC transfusion[g](#tbl1fng){ref-type="table-fn"}, %3.23.33.53.52.72.9APACHE II11.2 ± 6.212.2 ± 6.2[a](#tbl1fna){ref-type="table-fn"}14.3 ± 7.2[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}12.3 ± 5.9[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}13.4 ± 6.5[b](#tbl1fnb){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}15.6 ± 7.8[b](#tbl1fnb){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}Nonrenal SOFA3 (1--6)4 (2--7)[b](#tbl1fnb){ref-type="table-fn"}6 (3--9)[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}4 (2--6)[a](#tbl1fna){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}4 (2--7)[b](#tbl1fnb){ref-type="table-fn"}6 (3--10)[b](#tbl1fnb){ref-type="table-fn"}^,^[e](#tbl1fne){ref-type="table-fn"}[^2][^3][^4][^5][^6][^7][^8][^9][^10]

Ninety-Day Mortality Outcome {#sec2.2}
----------------------------

The crude 90-day mortality rate was 26.7%. Crude mortality proportions and time-to-event analysis in the 6 CKD/AKI study groups are shown in [Table 2](#tbl2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}, respectively. The 90-day mortality was lowest in the no-CKD/no-AKI group (17.4%), closely followed, in ascending order, by CKD/no-AKI (19.7%), CKD/AKI 1 (22.5%), and no-CKD/AKI 1 (25.6%). Groups with AKI ≥2, either with or without CKD, had the highest mortality, which was above 40% in both groups ([Table 2](#tbl2){ref-type="table"}).Table 2Crude proportion of study outcomes stratified by the 6 CKD/AKI groupsGroup90-Day mortalityIncident/progressive CKDno-CKD no-AKI104/598 (17.4%)33/321 (10.3%) AKI 193/363 (25.6%)42/183 (22.9%) AKI ≥2193/460 (42.0%)51/175 (29.1%)CKD no-AKI106/537 (19.7%)24/259 (9.3%) AKI 182/364 (22.5%)20/181 (11.0%) AKI ≥2125/310 (40.3%)33/116 (28.4%)[^11][^12]Figure 2Ninety-day mortality across chronic kidney disease (CKD)/acute kidney injury (AKI) groups. For the purpose of clarity, the no-CKD and CKD groups are represented on the left and right chart, respectively. no-CKD: baseline eGFR ≥60; CKD: baseline eGFR \<60; no-AKI: no AKI occurrence; AKI 1: KDIGO-sCr stage 1 AKI; AKI ≥2: KDIGO-sCr stage 2 or higher. ICU, intensive care unit; KDIGO, Kidney Disease: Improving Global Outcomes; sCr, serum creatinine.

After multivariable adjustment for demographic and clinical variables relative to the reference group of no-CKD/no-AKI, the risk for 90-day mortality significantly increased in a stepwise incremental fashion according to the presence and severity of AKI in the no-CKD groups ([Table 3](#tbl3){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}a). The CKD/no-AKI and CKD/AKI 1 groups were associated with a slight, but statistically non-significant, increase in the risk of 90-day mortality. Importantly, the risk for 90-day mortality significantly increased in the CKD/AKI ≥2 group (adjusted hazard ratio = 2.23, 95% confidence interval = 1.71−2.91), similarly to the corresponding no-CKD counterparts (adjusted hazard ratio = 2.45, 95% confidence interval = 1.92−3.12) ([Table 3](#tbl3){ref-type="table"}).Table 3Multivariable models for 90-day mortality (dependent variable) in the 6 CKD/AKI groups (independent variable)VariableModel 1 aHR (95% CI)*P*Model 2 aHR (95% CI)*P*no-CKD no-AKIReferenceReference AKI 11.50 (1.13--1.99)0.0051.50 (1.13--1.98)0.005 AKI ≥22.45 (1.92--3.12)\<0.0012.44 (1.92--3.11)\<0.001CKD no-AKI1.06 (0.81--1.40)0.6571.07 (0.82--1.41)0.609 AKI 11.19 (0.89--1.60)0.2381.19 (0.89--1.60)0.245 AKI ≥22.23 (1.71--2.91)\<0.0012.22 (1.70--2.89)\<0.001Age, per 1 yr1.02 (1.01--1.03)\<0.0011.02 (1.01--1.03)\<0.001African American0.88 (0.75--1.02)0.0980.89 (0.76--1.04)0.127Male gender1.08 (0.93--1.26)0.3251.08 (0.93--1.26)0.321Diabetes0.89 (0.74--1.08)0.2390.89 (0.74--1.08)0.239Systolic heart failure0.68 (0.43--1.09)0.111---Anemia1.29 (1.01--1.66)0.0461.29 (1.00--1.65)0.049Nonrenal SOFA ≥41.38 (1.16--1.66)\<0.0011.39 (1.16--1.66)\<0.001Mechanical ventilation2.22 (1.88--2.62)\<0.0012.21 (1.87--2.60)\<0.001RBC transfusion1.32 (0.89--1.99)0.171---Exposure to statins0.68 (0.57--0.81)\<0.0010.67 (0.56--0.80)\<0.001[^13][^14]Figure 3Adjusted hazard ratios (aHRs) for study outcomes. Summary of adjusted hazard ratios (dots) and 95% confidence intervals (lines) for (a) 90-day mortality (model 1) and (b) incident/progressive chronic kidney disease (CKD) (model 1). no-CKD: baseline eGFR ≥60; CKD: baseline eGFR \<60; no-AKI: no AKI occurrence; AKI 1: KDIGO-sCr stage 1 AKI; AKI ≥2: KDIGO-sCr stage 2 or higher. AKI, acute kidney injury; KDIGO, Kidney Disease: Improving Global Outcomes; sCr, serum creatinine.

Other variables independently associated with 90-day mortality were age, nonrenal SOFA score ≥4, mechanical ventilation, anemia at ICU admission (all positive associations), and statin exposure in the first 72 hours of ICU stay (negative association) ([Table 3](#tbl3){ref-type="table"}).

Incident/Progressive CKD Outcome {#sec2.3}
--------------------------------

Follow-up sCr was available in 1235 patients, corresponding to 64.0% of ICU survivors at 90 days postdischarge. Median follow-up time was 15.3 (5.7−29.2) months. The proportions of the incident/progressive CKD outcome and the corresponding adjusted hazard ratios for the CKD/AKI groups, in reference to no-CKD/no-AKI, are summarized in [Tables 2](#tbl2){ref-type="table"} and [4](#tbl4){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}b.Table 4Multivariable models for incident/progressive CKD (dependent variable) in the 6 CKD/AKI groups (independent variable)VariableModel 1 aHR (95% CI)*p*Model 2 aHR (95% CI)*P*no-CKD no-AKIReferenceReference AKI 12.11 (1.33--3.35)0.0012.13 (1.34--3.37)0.001 AKI ≥22.72 (1.74--4.25)\<0.0012.79 (1.79--4.34)\<0.001CKD no-AKI0.92 (0.54--1.58)0.7690.94 (0.55--1.61)0.835 AKI 10.95 (0.54--1.67)0.8630.96 (0.54--1.68)0.878 AKI ≥22.21 (1.35--3.64)0.0022.33 (1.43--3.80)\<0.001Age, per 1 yr1.01 (1.00--1.02)0.0931.01 (1.00--1.02)0.112African American1.28 (0.97--1.71)0.0831.28 (0.96--1.70)0.087Male gender0.98 (0.74--1.30)0.8800.98 (0.74--1.29)0.867Diabetes0.98 (0.71--1.36)0.9240.98 (0.71--1.36)0.921Systolic heart failure0.85 (0.40--1.82)0.678---Anemia1.87 (1.10--3.18)0.0211.88 (1.11--3.19)0.019Nonrenal SOFA ≥41.57 (1.14--2.15)0.0051.48 (1.11--1.98)0.008Mechanical ventilation0.83 (0.60--1.15)0.259---RBC transfusion0.87 (0.35--2.13)0.760---LOS, per 1 d1.11 (0.81--1.51)0.505---Exposure to statins0.93 (0.69--1.27)0.671---[^15][^16]

Similar to the 90-day mortality outcome, in patients without baseline CKD, the risk for incident CKD increased in a stepwise fashion by AKI severity. In the presence of pre-existing CKD, however, the risk of progressive CKD was significantly higher only in patients with AKI ≥2 ([Table 4](#tbl4){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}b). Factors independently associated with incident/progressive CKD were nonrenal SOFA ≥4 and anemia at ICU admission (all positive associations) ([Table 4](#tbl4){ref-type="table"}). Crude mortality during follow-up was 6.5% and 9.3% among patients with and without baseline CKD, respectively.

Sensitivity Analyses {#sec2.4}
--------------------

### Examination of AKI Stage 1 Based on Absolute and Relative Changes in sCr {#sec2.4.1}

We reclassified patients with AKI stage 1 into 2 groups according to whether they met the criterion of relative increase in sCr 1.5 to 1.9 times baseline (AKI 1-relative) or not (AKI 1-absolute). The main purpose of this sensitivity analysis was to test whether, in the presence of baseline CKD, the 2 groups of stage 1 AKI were differentially associated with study outcomes. Similar to our primary analysis, the adjusted hazard ratios (95% confidence intervals) for 90-day mortality were 1.16 (0.82−1.64) and 1.25 (0.84−1.85) in CKD/AKI 1-absolute and CKD/AKI 1-relative, respectively (reference no-CKD/no-AKI). Concordant findings were observed for incident/progressive CKD. The complete results are reported in [Supplementary Tables S1 and S2](#appsec1){ref-type="sec"}.

### Examination of Potential Misclassification of AKI as CKD When Assessing CKD Outcome {#sec2.4.2}

We found that only 10 patients had 2 follow-up SCr measurements \<7 days apart and were reclassified in relation to their CKD outcome if single last SCr or the mean of the last 2 sCr measurements was used. After excluding these 10 patients in addition to patients with the upper and lower 2.5% of the distribution for percentage change in follow-up eGFR from baseline (n = 36), the multivariable analysis showed concordant findings with our primary analysis ([Supplementary Table S3](#appsec1){ref-type="sec"}).

Discussion {#sec3}
==========

We studied how prevalent CKD and incident AKI jointly affect the prognosis of critically ill patients with sepsis. Our key finding is that, in the presence of underlying CKD, AKI stage 2 or 3, but not stage 1, was independently associated with increased risk of 90-day mortality and progressive CKD during the median observation period of 15.3 months. In contrast, in patients without pre-existing CKD, the risk of 90-day mortality and incident CKD significantly increased in a stepwise incremental fashion according to the stages of AKI severity.

Previous reports have suggested that pre-existing CKD might attenuate the adverse prognosis of patients with AKI.[@bib28], [@bib29], [@bib31], [@bib32] For instance, in the Program to Improve Care in Acute Renal Disease (PICARD) study, a prospective cohort of critically ill patients with AKI, prior history of CKD was independently associated with reduced in-hospital mortality and shorter length of ICU stay in AKI patients.[@bib32] Our results seem congruent with the observation that prevalent CKD does not significantly worsen prognosis in critically ill patients with mild AKI. However, these findings are not fully concordant with those of other studies. For example, Thakar *et al.* described a cohort of more than 30,000 subjects undergoing elective or emergent cardiac surgery and, after adjustment for confounders, found that AKI patients with underlying CKD had a higher risk of hospital mortality than those without CKD.[@bib47] It is interesting that in that cohort, any degree of CKD, independently of AKI, conferred an excess risk of mortality. On the contrary, we found that prevalent CKD without incident AKI was not independently associated with an increased risk of 90-day mortality. This divergence could be due to differences in the study populations, with CKD *per se* playing a key role in more stable cardiac surgery patients but a less relevant role in our cohort of critically ill septic patients (2.2% vs. 26.7% all-cause mortality, respectively).

Another study reporting CKD/AKI-associated outcomes was conducted in more than 43,000 hospitalized patients in Canada.[@bib48] Notably, prevalent CKD without incident AKI was found to be independently associated with in-hospital mortality, but only in patients with baseline eGFR \<30 ml/min per 1.73 m^2^. This may help in interpreting our findings, as only one-fourth of our CKD patients had a baseline eGFR \<30 ml/min per 1.73 m^2^, possibly attenuating the putative association. Similar to our study, the authors reported that the risk of in-hospital mortality for AKI patients with pre-existing CKD was similar or lower than their counterparts with the same AKI severity, but no CKD.[@bib48] However, discrepant with our analysis is that stage 1 AKI was associated with excess risk of in-hospital mortality across all strata of baseline eGFR. It is possible that the smaller sample size of our study limited statistical power and the ability to detect small effects. Alternatively, our findings might suggest that the prognostic impact of stage 1 AKI is attenuated in patients with underlying CKD. This phenomenon may be specific to critically ill septic patients, as opposed to a generic group of hospitalized patients in the Canadian study.[@bib48]

Interestingly, the analysis of the outcome of incident or progressive CKD during the median observation period of 15.3 months revealed a pattern similar to the 90-day mortality outcome. In patients without prevalent CKD, any level of AKI worsened outcomes in a stepwise incremental fashion according to AKI severity, whereas in the presence of baseline CKD, only AKI stage 2 or above conferred a significant excess in risk. These findings reinforce the notion that, in the setting of severe sepsis or septic shock, the diagnosis of stage 1 AKI, when superimposed on CKD, did not significantly worsen prognosis, in either the short- or long-term follow-up. One explanation for this is that, in the presence of CKD, the definition of stage 1 AKI may capture erratic oscillations in sCr of limited clinical significance. This was shown to be the case in a cohort of hospitalized veterans, in which an increase in sCr of 26.4 to 35.2 μmol/l (0.3−0.4 mg/dl) during hospital admission was associated with excess in-hospital mortality only in patients with baseline eGFR above 30 ml/min per 1.73 m^2^, but not in those with CKD stages 4 to 5.[@bib49] Similarly, Lin *et al.* demonstrated that, in the setting of higher baseline sCr levels, the inherent biological and laboratory variation in sCr measurement contributes to a substantial rate of false-positive cases of AKI, especially when the criterion of absolute increase in sCr is applied to define AKI.[@bib50] However, our sensitivity analysis suggests that the use of absolute sCr increases to classify AKI stage 1 did not influence our findings.

An alternative explanation is that, in the setting of sepsis, AKI on CKD, specifically stage 1 AKI, is pathophysiologically distinct from that found in patients without underlying CKD. Transient renal hypoperfusion frequently occurs in sepsis and is likely to result in appreciable increases in sCr in patients with CKD who already have diminished renal reserve. In contrast, transient renal hypoperfusion can remain subclinical in subjects with well-preserved baseline renal function. Therefore, cases of stage 1 AKI on CKD, compared with their counterparts without CKD, may reflect lesser degrees of underlying renal/systemic injury and entail a greater component of prerenal pathophysiology, with limited or no *de novo* intrinsic renal damage. An additional observation supporting this hypothesis was made by Kellum *et al.* when they reported that patients with sepsis-associated AKI who recover partial or complete renal function had long-term survival similar to that in patients without AKI.[@bib51] Interestingly, experimental data suggest that pre-existing CKD could limit further kidney damage in response to renal insults, which could also contribute to mitigate post-AKI outcomes in CKD patients.[@bib52], [@bib53] For instance, following an ischemia/reperfusion challenge, rats that had undergone a significant ablation of renal mass developed a blunted degree of acute tubular necrosis and less parenchymal infiltration by inflammatory cells, compared to control animals with normal kidneys.[@bib53] It has been proposed that this may be the result of complex pathophysiological adaptations that occur in the setting of chronically reduced nephron mass, culminating in a protective influence of prior kidney injury on acute parenchymal damage.[@bib54] As shown by measurement[@bib55] or modeling,[@bib56] chronically low GFR and corresponding low tubular Na^+^ reabsorption reduce O~2~ consumption in the kidney, and potentially protect it from ischemia. It is also possible that pre-existing kidney damage may favorably alter the response to sepsis-associated renal injury to a greater extent than to other nephrotoxic insults. However, the current understanding of CKD-related renal adaptations is still very limited, and this remains merely a hypothesis at present.

Our study has several strengths. Unlike most of the previous analyses focusing on the joint prognostic effects of CKD and AKI, we adopted a consensus sCr-based definition of AKI and incorporated AKI severity in the analysis, which makes our results more relevant to clinical practice. Another asset is that we did not only examine 90-day mortality, but also considered adverse renal outcomes over a prolonged follow-up period. Finally, we performed sensitivity analyses to examine the differential effect of absolute and relative changes in sCr (used to define AKI stage 1) on study outcomes and to address the potential misclassification of AKI as CKD when assessing the CKD outcome.

We also acknowledge that our study has limitations. First, it is retrospective in nature and derived using ICD-9-CM codes to determine sepsis diagnosis. We relied on EHR data obtained in routine clinical care, with the inherent possibility of selection bias and attrition due to missing data. Second, prevalent CKD was defined on the basis of only 1 sCr measurement, which may have led to misclassification. Nonetheless, we defined CKD using exclusively sCr measurements within 3 months before hospitalization and did not consider admission sCr for the purpose of CKD determination, thus avoiding a major reason for possible misclassification of AKI as CKD. Third, the determination of the CKD outcome was based on 1 or 2 sCr measurements obtained during the observation period, which may be susceptible to misclassification of AKI as CKD. However, we performed sensitivity analyses to further validate our findings. Finally, we defined AKI based only on changes in sCr and did not incorporate the KDIGO urine output criterion. However, this is the case also for the vast majority of other retrospective clinical studies of AKI, and thus makes the findings more comparable across different cohorts.

Conclusion {#sec4}
==========

We studied how prevalent CKD and incident AKI interact to affect outcomes in critically ill septic patients. We found that, in the presence of pre-existing CKD, AKI stage 1 did not significantly increase the risk of 90-day mortality and progressive CKD. However, AKI stage 2 or higher in those patients with baseline CKD, and each stage of AKI in those without baseline CKD, significantly increased adverse outcomes. These findings raise the hypothesis that stage 1 AKI on prevalent CKD in critically ill septic patients could reflect distinct AKI pathophysiology. In particular, functional or transient forms of AKI, with a limited extent of intrinsic damage, could be represented primarily among septic patients with stage 1 AKI superimposed on CKD. Further collection of comprehensive prospective clinical data characterizing AKI severity, duration, and recovery phenotypes and incorporating biomarker information, tissue interrogation, and novel imaging technologies will hopefully offer fresh insights into the pathophysiology of sepsis-associated AKI and its complex interplay with CKD.
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[^1]: JAN and FM contributed equally to this work.

[^2]: APACHE II, Acute Physiology and Chronic Health Evaluation II; CFB, cumulative fluid balance; eGFR, estimated glomerular filtration rate; LOS, length of stay in the hospital; RBC, red blood cell; sCr, serum creatinine; SOFA, Sequential Organ Failure Assessment.

[^3]: Data are presented as mean ± SD, median (25th--75th percentile), or percentage. APACHE II and nonrenal SOFA scores were calculated with data from the first 24 hours of ICU stay.

[^4]: Significant difference (*P* \< 0.05) relative to reference group no-CKD/no-AKI.

[^5]: Significant difference (*P* \< 0.001) relative to reference group no-CKD/no-AKI.

[^6]: Significant difference (*P* \< 0.001) between the CKD group and the correspondent no-CKD group with the same AKI status (CKD/no-AKI vs. no-CKD/no-AKI; CKD/AKI 1 vs. no-CKD/AKI 1; CKD/AKI ≥2 vs. no-CKD/AKI ≥2).

[^7]: Significant *P* for trend (*P* \< 0.05) across the different AKI status groups, either in no-CKD or CKD (trend across no-CKD/no-AKI, no-CKD/AKI 1 and no-CKD/AKI ≥2 or across CKD/no-AKI, CKD/AKI 1 and CKD/AKI ≥2).

[^8]: Significant *P* for trend (*P* \< 0.001, respectively) across the different AKI status groups, either in no-CKD or CKD (trend across no-CKD/no-AKI, no-CKD/AKI 1 and no-CKD/AKI ≥2 or across CKD/no-AKI, CKD/AKI 1 and CKD/AKI ≥2).

[^9]: Significant difference (*P* \< 0.05) between the CKD group and the correspondent no-CKD group with the same AKI status (CKD/no-AKI vs. no-CKD/no-AKI; CKD/AKI 1 vs. no-CKD/AKI 1; CKD/AKI ≥2 vs. no-CKD/AKI ≥2).

[^10]: Exposure to drugs/RBC transfusions was based on the first 72 hours of intensive care unit admission.

[^11]: AKI, acute kidney injury; CKD, chronic kidney disease.

[^12]: The 90-day mortality denotes all-cause death during index hospital admission or within 90 days of hospital discharge. Incident/progressive CKD (in patients without and with baseline CKD, respectively) was adjudicated in survivors during median follow-up of 15.3 months.

[^13]: APACHE II score was not included in the models due to collinearity with the SOFA score; aHR, adjusted hazard ratio; AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval; CKD, chronic kidney disease; RBC, red blood cell; SOFA, Sequential Organ Failure Assessment.

[^14]: Data are aHRs and 95% CIs for 90-day mortality by Cox proportional hazard regression. Model 1 includes all tested variables, whereas model 2 includes variables of deemed particular clinical relevance (age, race, gender, diabetes), together with additional variables that were retained through backward selection (cut-off for retention: *P* \< 0.10).

[^15]: APACHE II score was not included in the models due to collinearity with the SOFA score; aHR, adjusted hazard ratio; AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval; CKD, chronic kidney disease; LOS, length of stay in the hospital; RBC, red blood cells; SOFA, Sequential Organ Failure Assessment.

[^16]: Data are aHRs and 95% CIs for incident/progressive CKD by Cox proportional hazard regression. Model 1 included all tested variables, while model 2 includes variables of deemed particular clinical relevance (age, race, gender, diabetes), together with additional variables that were retained through backward selection (cut-off for retention: *P* \< 0.10).
